

## PRESCRIBING INFORMATION

## PRESENTATION

## USES

## DOSAGE AND ADMINISTRATION

**Recommended dosage:**

### PREPARATION OF SOLUTION

### CONTRA-INDICATIONS, WARNINGS, ETC.

**Precautions:**

**Overdosage:**

**Side-effects:**

## PHARMACEUTICAL PRECAUTIONS

**LEGAL CATEGORY**

## PACKAGE QUANTITIES

## FURTHER INFORMATION

**PRODUCT LICENCE NUMBER**

**N.H.S. Price £ 28**

# Somatronorm®

Recombinant Growth Hormone

somatrem

**Karl V. Murray (Edr.)** - **Cashill May Roberts Ltd.**, PO Box 1090  
Chapel Road, Dublin 20. Tel. Dublin 267111

[illegible]

of biotechnology-related  
labor firms continuing  
commitment in the field  
of growth and  
growth factors

Second Edition

# EPIDEMIOLOGY FOR THE UNINITIATED

GEOFFREY ROSE, D J P BARKER

## *Get a working knowledge of epidemiology*

No one would expect to understand a disease without knowledge of its clinical findings and pathology, but a surprising number of doctors remain ignorant of another important aspect – the study of disease in relation to populations. Epidemiology has its own techniques of data collection and interpretation and its necessary jargon of technical terms, and in *Epidemiology for the Uninitiated* Professors Geoffrey Rose and David Barker guide the novice expertly through the theory and practical pitfalls. The second edition of this popular *BMJ* handbook has been revised to include further details of epidemiological methods and some of their more dramatic applications, such as the investigations on the Spanish cooking oil epidemic, and AIDS.

Price: Inland £3.95;  
Abroad £5.50; USA \$8.50  
BMA members; Inland £3.45;  
Abroad £5.00; USA \$7.50

*(Please quote membership number)*  
*Prices include postage, by air abroad.*  
**Payment must be enclosed with order.**

## BOOKS FROM THE BMJ

Order from  
The Publishing Manager, British Medical Journal,  
BMA House, Tavistock Square, London WC1H 9JR  
or any leading bookseller

### Abbreviated Prescribing Information

'HUMULIN' S ▼ 'HUMULIN' I ▼  
'HUMULIN' Zn ▼ 'HUMULIN' M1 ▼  
'HUMULIN' M2 ▼ Human insulin (crb)

**Presentation:** **Humulin S:** A sterile, aqueous solution of human insulin (crb). **Humulin I:** A sterile suspension of isophane human insulin (crb). **Humulin Zn:** A sterile suspension of crystalline human insulin (crb) zinc suspension.

**Humulin M1:** A sterile suspension of human insulin (crb) in the proportion of 10% soluble insulin and 90% isophane insulin. **Humulin M2:** A sterile suspension of human insulin (crb) in the proportion of 20% soluble insulin and 80% isophane insulin. Each presentation contains 100 IU/ml. **Uses:** For the treatment of insulin-dependent diabetes mellitus.

**Dosage and Administration:** The dosage should be determined by the physician, according to the requirements of the patient. Humulin S may be administered by subcutaneous, intramuscular or intravenous injection. Humulin I, Humulin Zn, Humulin M1 and Humulin M2 should be administered by subcutaneous or intramuscular injection only. Humulin S may be administered in combination with Humulin I or Humulin Zn as required. **Humulin I, Zn, M1 and M2:** Rotate vial in palms of hands immediately before use to re-suspend. **Mixing of insulins:** The shorter-acting insulin should be drawn into the syringe first, to prevent contamination of the vial by the longer-acting preparation. It is advisable to inject immediately after mixing. **Contra-indications,**

**Warnings, etc. Contra-indications:** Hypoglycaemia. Under no circumstances should Humulin I, Humulin Zn, Humulin M1 or Humulin M2 be given intravenously. **Precautions: Usage in pregnancy:** Insulin requirements usually fall during the first trimester and increase during the second and third trimesters. **Transferring from other insulins:** A small number of patients transferring from insulins of animal origin may require a reduced dosage and/or a change in the ratio of soluble to intermediate preparations, especially if they are very tightly controlled and bordering on hypoglycaemia. The risk of hypoglycaemia can be considered minimal if the daily dosage is less than 40 IU. Insulin-resistant patients receiving more than 100 IU daily should be referred to hospital for transfer. **Side-effects:** Lipodystrophy, insulin resistance and hypersensitivity have rarely been reported. **Legal**

**Category:** P. **Package Quantities:** 10ml glass vials in packs of 5. **Price:** Humulin S: 100 IU/ml. £6.68; Humulin I: 100 IU/ml. £6.68; Humulin Zn: 100 IU/ml. £6.68; Humulin M1: 100 IU/ml. £6.68; Humulin M2: 100 IU/ml. £6.68. **Product Licence Numbers, Name and Address:** Humulin S 100 IU/ml 0006/0165 Humulin I 100 IU/ml 0006/0168 Humulin Zn 100 IU/ml 0006/0179 Humulin M1 100 IU/ml 0006/0199 Humulin M2 100 IU/ml 0006/0200. **Date of Preparation:** January 1986.

**References:** 1. Corcoran, J.S. and Yudkin, J.S. *Diabetic Medicine*, 1985, 2, 131-133. 2. Fineberg, S.E. *et al. Diabetologia*, 1983, 25, 465-469.

### Full Prescribing Information Available From:

Eli Lilly and Company Limited,  
Kingsclere Road, Basingstoke,  
Hampshire RG21 2XA.  
Telephone: Basingstoke  
(0256) 473241.

'HUMULIN' is a Lilly trade mark

Hu 141 March 1986





# He's running on the new M2.

He has found that a B.D. dose of the new Humulin M2 closely matches his daily insulin requirements.

The 20/80 mixture of Humulin S (soluble) and Humulin I (isophane) provides both a rapid action and prolonged effect that fit his needs.

In another patient with a lower soluble insulin requirement, Humulin M1, containing 10% soluble and 90% isophane, might be more suitable.

All this with a consistency and

convenience that cannot usually be achieved with free mixing.<sup>1</sup>

Like all Humulin products, M1 and M2 share the unique benefits of human insulin produced by genetic engineering: low immunogenicity,<sup>2</sup> unlimited future supply and at a cost comparable with pork or enzymatically modified insulins.

**Humulin**  
Human insulin (crb)  
**MIXTURES**

Consistency and convenience with low immunogenicity



# Epilim<sup>®</sup>

sodium valproate

**Presentation 1:** Epilim 200 Enteric Coated. A lilac-coloured enteric coated tablet containing 200mg sodium valproate. **Presentation 2:** Epilim 500 Enteric Coated. A lilac-coloured enteric coated tablet containing 500mg

sodium valproate. **Presentation 3:** Epilim 100mg crushable tablets. A white scored tablet containing 100mg sodium valproate. **Presentation 4:** Epilim Syrup. A red, cherry-flavoured syrup containing 200mg sodium valproate per 5ml. **Presentation 5:** Epilim Liquid. A red, cherry-flavoured, sugar-free liquid containing 200mg sodium valproate per 5ml. **Indications** In the treatment of generalised, partial or other epilepsies. In women of child-bearing age Epilim should be used only in severe cases or in those resistant to other treatment. **Dosage and Administration** To be taken with or after food. Epilim may be given twice daily. Enteric coated tablets should be swallowed whole. **Monotherapy Adults:** Start at 600mg/daily increasing by 200mg at 3 day intervals until control is achieved. (Maximum dose 2.500mg per day). **Children over 20kg:** Initially 400mg/day with spaced increases until control is achieved. (Usually within the range 20-30mg/kg body weight per day). **Children under 20kg:** 20mg/kg of body weight per day in severe cases may be increased up to 40mg/kg day. Increases above this only if plasma valproic acid levels, clinical chemistry and haematological parameters can be monitored. **Combined Therapy** It may be necessary to raise the dose when used with anticonvulsants which induce liver enzyme activity. Dosage of barbiturates should be reduced if sedation is observed. Optimum dosage is mainly determined by seizure control and routine measurement of plasma levels is unnecessary. **Contra-indications, Warnings; Contra-indication:** Active liver disease. **Side effects:** Liver dysfunction including hepatic failure resulting in fatalities has occurred in patients whose treatment included valproic acid or sodium valproate. The incidents mainly occurred during the first 6 months of therapy. Clinical symptoms are more helpful than laboratory investigations in the early stages of hepatic failure. The onset of an acute illness, especially within the first 6 months, which may include symptoms of vomiting, lethargy or weakness, drowsiness, anorexia, jaundice or loss of seizure control is an indication for immediate withdrawal of the drug. Evidence to date does not establish which investigation could predict this possible adverse effect: measurement of liver function should be performed in the first 6 months of therapy in those who seem most at risk. Hyperammonaemia without hepatic damage can occur, it is usually transient, but may occasionally present clinically. If so Epilim should be discontinued. Valproic acid inhibits platelet aggregation. Thrombocytopenia has been reported. Spontaneous bruising or bleeding is an indication for withdrawal of medication. Pancreatitis, tremor, weight gain, transient hair loss, increased alertness, aggressiveness, hyperactivity, amenorrhoea, stupor and oedema have been reported. **Drug Interactions** Epilim may potentiate monoamine oxidase inhibitors and other anti-depressants. Loss of efficacy of oral contraceptive agents does not appear to be a problem. **Women of Childbearing Age** Valproic acid and sodium valproate, like certain other anti-convulsants, have been shown to be teratogenic in animals. In women of childbearing age the benefits of these compounds should be weighed against the possible hazard suggested by these findings and their pregnancies should be carefully monitored. **Product Licence Numbers** Epilim 200 Enteric Coated 0623/0005. Epilim 500 Enteric Coated 0623/0005. Epilim 100mg crushable tablets 0623/0015. Epilim Syrup 0623/0004. Epilim Liquid 0623/0016. **NHS Cost** Epilim 200 Enteric Coated 100 tablets, £6.59. Epilim 500 Enteric Coated 100 tablets, £16.45. Epilim 100mg crushable tablets 100 tablets, £3.99. Epilim Syrup 200ml, £4.03. Epilim Liquid 200ml, £4.03. Further information is available from Labaz: Sanofi UK Ltd., Floats Rd., Wythenshawe, Manchester M23 9NF. Tel: 061-945 4161.

*In a wide range of epilepsies*



**Epilim<sup>®</sup>**  
sodium valproate

*helps to maintain the normality of life*

# Effective asthma control in the pre-school child

**Intal<sup>®</sup>**  
Sodium Cromoglycate BP  
Nebuliser Solution  
right from the start



#### Prescribing Information

**Presentation** Ampoules containing Sodium Cromoglycate BP 20mg in 2ml sterile aqueous solution.  
**Uses** Preventive treatment of bronchial asthma. Also prevents the bronchoconstriction caused by exercise, cold air and chemical irritants. **Dosage and Administration** Since Intal Nebuliser Solution therapy is preventive, it is important that regular dosages be maintained, as distinct from intermittent use to relieve symptoms. Adults and children: the contents of one ampoule are administered by nebulisation using a suitable power-operated nebuliser four


times daily. In severe cases frequency of administration may be increased to 5 or 6 times daily. **Contraindications, Warnings etc.** There are no specific contraindications. Intal Nebuliser Solution must not be given by injection. **Side effects** Occasional irritation of the throat and in rare cases severe bronchospasm have been reported with powder forms of Sodium Cromoglycate. **Basic NHS Cost and Product Licence Number** £9.43 for 48 x 2ml ampoules P/L 0113/0068  
\* Registered trade mark

**FISONS**

Pharmaceuticals

FISONS plc - PHARMACEUTICAL DIVISION 12 Derby Road, Loughborough, Leicestershire LE11 0BB.

# An addition to the family-



**For small  
and fragile  
veins**

## **Neoflon™ Intravenous Cannula**

**Neoflon™ is part of the Venflon range of I.V. Cannulae but has been specifically designed for Neonatal, small and fragile vein cannulation.**

### **Design**

The unique design of Neoflon with its detachable wing-holder makes the product, despite its small size, easy to hold and gives a Venflon type grip to ensure convenient and precise venepuncture.

### **Construction**

Made from P.T.F.E. and with the Cannula tip tapered and bevelled insertion is facilitated with the risk of kinking and peelback minimised.


### **Fixing**

The flexible wings facilitate secure fixation reducing the incidence of mechanical irritation.

*For further information please phone or write to  
British Viggo in Swindon.*

*International customers please contact Viggo International Sales.*

TM Viggo Trade Mark



# **Viggo**

British Viggo  
Faraday Road  
Swindon  
Wiltshire SN3 5HZ  
Tel: 0793 641791  
Telex: 444443 VIGGO G

BOC Health Care

Viggo International Sales  
Chertsey Road  
Windlesham  
Surrey GU20 6HQ  
Tel: 0276 77222  
Telex: 899363 BOC GHQ G  
Fax No: 0276 71333

# International coverage of the most important developments in pediatric medicine

## PEDIATRIC RESEARCH

*An International Journal of Clinical, Laboratory, and Developmental Investigation*


Editor-in-Chief: Delbert A. Fisher, MD

Every month, **Pediatric Research** puts you in touch with leading authorities in pediatric pulmonology, endocrinology and metabolism, gastroenterology, and nutrition. You'll read about significant new clinical and laboratory results, as selected and reported by an international array of distinguished contributors and editors.

Abstracts of major society meetings worldwide and occasional supplements on specific issues in pediatric health are also part of the package, but the hallmark of **Pediatric Research** is *research*, and lots of it. Each issue contains some 15 original articles — 4 to 6 pages each — on late-breaking investigations into the most difficult problems of childhood disease.

Cystic fibrosis, hypopituitarism, sudden infant death syndrome, protein intolerance, metabolic disorders, and sickle cell anemia are just a few of the subjects covered in recent issues. As advances are made in the understanding and management of these and other baffling childhood disorders, **Pediatric Research** will continue to be there with timely, accurate, and useful reports from leaders in the field. **Monthly**

**Personal: \$90/yr Institutions: \$115/yr.**  
**In-training: \$70/yr** (add \$15.00 outside the US)



FOR FASTEST SERVICE, call 1-800-638-6423 FREE  
from anywhere in the US except AK and HI. MD  
residents, call 528-4105 collect.



P.O. Box 1496 Baltimore, Maryland 21203  
266 Fulham Road London SW10 9EL England



## PEDIATRIC RESEARCH *An International Journal of Clinical, Laboratory, and Developmental Investigation*

**Research you can't afford to miss... and an offer you can't afford to pass up**

Avoid planned rate increases and ensure uninterrupted service by subscribing to **PEDIATRIC RESEARCH** for up to 3 years at current rates.

- ☐ New subscription ☐ Renewal  
☐ 3 yrs ☐ 2 yrs ☐ 1 yr  
☐ **Personal: \$90/yr** ☐ **Institutions: \$115/yr**  
☐ **In-training: \$70/yr**  
(add \$15.00 outside the US)  
☐ check enclosed ☐ bill me  
☐ VISA ☐ MasterCard ☐ American Express

card # \_\_\_\_\_ exp. \_\_\_\_\_  
signature/P.O. # \_\_\_\_\_

**Williams & Wilkins**

MD residents, please add 5% sales tax. Subscriptions outside the US must be prepaid, in US dollars only. *Residents, fellows, interns, and students:* when applying for the in-training rate, which is limited to three years, please include institution name and training status. Rates valid through October 31, 1986.

Please allow 8 weeks for delivery of your first issue. Surface mail delivery to countries outside the US may take up to 16 weeks. Airmail rates available upon request.

Name \_\_\_\_\_  
Address \_\_\_\_\_  
City/State/Zip \_\_\_\_\_

P.O. Box 1496 Baltimore, Maryland 21203  
266 Fulham Road London SW10 9EL England  
printed in USA



PDRAD 94454 86



# Monatsschrift Kinder- heilkunde

Organ der  
Deutschen Gesellschaft  
für Kinderheilkunde

134. Band  
Heft 9  
September 1986

Springer-Verlag  
Berlin Heidelberg New York London  
Paris Tokyo

|   | <b>Thema des Monats</b>  | <b>This Month's Topic</b>  |      |
|---|--|--|------|
|   | Probleme bei sehr kleinen Frühgeborenen,<br>Teil III: Knochenwachstum, Elektroencephalo-<br>gramm und Krämpfe, hyaline Membranen, Vitamin<br>K-Prophylaxe  | Problems in Very Small Premature Babies,<br>Part III: Bone Growth, EEG and Convulsions, Hy-<br>aline Membranes, Vitamin K Prophylaxis  | 649  |
| H. Manzke, H. Schröder                              | Knochenstoffwechselstörungen bei Frühgeborenen   | Bone Metabolic Disorders Affecting the Bones of<br>Premature Infants   | 650  |
| J. Lütshg   | Entwicklung des Elektroencephalogramms und die<br>Bedeutung neonataler Krämpfe bei Frühgeborenen   | The Development of the EEG and the Interpre-<br>tation of Seizures in Preterm Babies   | 658  |
| A. Gerber   | Die Prophylaxe der Krankheit der hyalinen Mem-<br>branen   | Prevention of Respiratory Distress Syndrome  | 662  |
| R. v. Kries, U. Göbel                               | Neue Aspekte zur Vitamin K-Prophylaxe bei Neu-<br>geborenen und Säuglingen   | New Aspects of Vitamin K Prophylaxis in New-<br>borns and Infants  | 666  |
|   | <b>Pädiatrie aktuell</b>   | <b>Trends in Paediatrics</b>   | 672  |
|   | <b>Was hat das Kind?</b><br><b>Trainingsprogramm für die Weiterbildung<br/>zum Kinderarzt</b>  | <b>What's Wrong with the Child?</b><br><b>Program for Continuing Education<br/>of Paediatricians</b>   | 673  |
|   | <b>Aus Klinik und Forschung<br/>Originalien</b>  | <b>Clinic and Research<br/>Originals</b>   |      |
| J. Schwalbe, V. Hofmann                             | Sonografische Verlaufsbeobachtungen bei eitriger<br>Meningitis und ihren Komplikationen im Säug-<br>lingsalter   | Sonographic Observations in Meningitis and the<br>Complications in Infants   | 674  |
| O. Galal, I. Galal,<br>B. Preuss, J. Stoermer       | Nichtinvasive Diagnostik zur Beurteilung der<br>Shuntgröße bei Kindern mit Vorhofseptumdefekt  | Non-invasive Diagnostic Procedures to Judge the<br>Size of the Shunt in Atrial Septal Defect in<br>Children  | 678  |
| K. Rauber, J. Kollath                               | Digitale Subtraktionsangiographie bei Kindern<br>und Jugendlichen  | Digital Subtraction Angiography in Children  | 681  |
| G. Fritsch, E. Winkler,<br>A. Flanyek, W. D. Müller | Neurologische, psychologische und logopädische<br>Nachuntersuchung von 6- bis 8jährigen ehemaligen<br>Frühgeborenen mit einem Geburtsgewicht unter<br>1500 g   | Neurological, Psychological and Logopedic<br>Follow-up Observations in 6- to 8-Year-Old<br>Premature Infants with a Birth Weight Below<br>1500 g   | 687  |
|   | <b>Der interessante Fall</b>   | <b>Interesting Cases</b>   |      |
| P. Meinecke, R. Engelbrecht, E. Schaefer            | Coffin-Siris-Syndrom bei einem 5jährigen Mädchen   | The Coffin Siris Syndrome in a 5-Year-Old Girl   | 692  |
| W. Künzer, E. Struck,<br>R. Rohrbach, C. Hufschmidt | Hämolytisch-urämisches Syndrom im Gefolge<br>eines kindlichen Lupus erythematodes<br>disseminatus  | Hemolytic Uremic Syndrome Subsequent to<br>Systemic Lupus Erythematosus in a Child   | 696  |
| J. Ritter, Th. Pauly, H. Pollmann                   | Salmonellen Osteoarthritis bei Hämophilie A  | Septic Osteoarthritis Due to Salmonella in a<br>Hemophilic   | 701  |
|   | <b>Wußten Sie schon?</b><br><i>Neues aus Therapie und Prophylaxe</i>   | <b>Do You Know?</b><br><i>New Developments in Therapy and Prophylaxis</i>  |      |
| F. Bläker   | Offizielle Erklärung der Deutschen Gesellschaft für<br>Kinderheilkunde und der Deutschen Gesellschaft<br>für Kinder- und Jugendpsychiatrie zur Frage der<br>phosphatarmen Diät bei Kindern mit hyperkine-<br>tischem Syndrom | Official Announcement of the German Society of<br>Paediatrics and the German Society of Child and<br>Adolescent Psychiatry: the Low-Phosphate Diet<br>in Children with the Hyperkinetic Syndrome | 703  |
|   | <i>Aus der Praxis — für die Praxis</i>   | <i>Practical Tips for Practitioners</i>  |      |
| F. Schindra   | Zungenpapillom   | Papilloma of the Tongue  | 704  |
|   | Auflösung und Kommentar des Trainings-<br>programms für die Weiterbildung zum Kinderarzt   | Solution and Commentary in the Program for<br>Continuing Education of Paediatricians   | 686  |
|   | <b>Neue Bücher</b>   | <b>New Books</b>   | 705  |
|   | <b>Tagungskalender</b>   | <b>Forthcoming Meetings</b>  | 708  |
|   | <b>Für die Dokumentation</b>   | <b>Documentation</b>   | A 58 |

Indexed in Current Contents

Monatsschr Kinderheilkd (1986) 134, 9

**Annual subscription: DM 278,— plus postage**



# HOW TO DO IT

SECOND EDITION


The first edition of HOW TO DO IT proved a useful and popular guide to those things a doctor needs to know but is rarely taught: how to take an examination, how to interview and be interviewed, how to plan and write up research, how to behave at an inquest. In the second edition the original chapters have been expanded and updated, and there are several more chapters on new challenges—choosing a computer, flying, holding a press conference—and on some older ones not included in the first edition—assessing a job, dealing with a publisher.

Price: Inland £6.95  
Abroad £9.00/USA\$14.50  
BMA members: Inland £6.45  
Abroad £8.50/USA\$13.50  
*including postage, by air  
abroad*

Please quote  
membership number

**Payment must be enclosed  
with order**

Order from  
The Publishing Manager  
British Medical Journal  
BMA House, Tavistock Square  
London WC1H 9JR  
*or any leading bookseller*




*"Value judgements about food are being made all the time . . .*

# ABC OF NUTRITION

A STEWART TRUSWELL

*. . . they are nearly always subjective and usually wrong."* A Stewart Truswell, Boden professor of human nutrition at the University of Sydney, separates fact from fallacy in the *ABC of Nutrition*, a collection of articles from the *BMJ*. This illustrated guide offers the general medical reader a refreshingly down to earth review of all aspects of nutrition – from anorexia to obesity, infant feeding to dietary guides for the elderly – and will be invaluable for any doctor wishing to advise his patients about their eating habits (or even to revise his own).



**Chapters include:**

- Nutrition for pregnancy
- Enteral and parenteral nutrition
- Vitamins
- Malnutrition in the third world
- Therapeutic diets
- Reducing the risk of coronary heart disease
- Food sensitivity

Price: Inland £4.95; Abroad £6.75/USA\$10.00

BMA members: Inland £4.45; Abroad £6.25/USA\$9.00

*(Please quote membership number). Prices include postage, by air abroad.*

*Payments must be enclosed with order.*

## BOOKS FROM THE BMJ

Order from The Publishing Manager, British Medical Journal, BMA House, Tavistock Square,  
London WC1H 9JR or any leading bookseller

# PAEDIATRIC TITLES FROM BUTTERWORTHS

## PAEDIATRIC EMERGENCIES • Second Edition

Edited by **J A Black, MD, FRCP**

Formerly Consultant Paediatrician, Children's Hospital, Sheffield and Jessop Hospital for Women, Sheffield,  
Clinical Teacher, University of Sheffield

One of the main aims of the first edition was to make available to the general paediatrician the practice of the best specialist units. The second edition not only expands on the wealth of information and sound doctrine laid down in the earlier work but also remains true to its original aims.

This latest edition includes new chapters on solvent abuse, abdominal ascariasis, viral haemorrhagic fevers, brain death and acute liver failure. It will be essential reading not only for general paediatricians but for all those involved in the day-to-day medical care of children.

### Review of first edition

'It is a front line book, for the acute paediatric ward . . . Every paediatric department should have it.'

*Archives of Disease in Childhood*

November 1986 856 pages approx 234 × 165 mm Hardcover Illustrated 0 407 00280 4 £65.00 approx

## DIARRHOEA AND MALNUTRITION IN CHILDHOOD

Edited by **Professor J A Walker-Smith** and **Professor A S McNeish**

June 1986 264 pages 234 × 165 mm Softcover Illustrated 0 407 00401 7 £25.00

## FETAL AND NEONATAL PHYSIOLOGICAL MEASUREMENTS

Edited by **Peter Rolfe**

September 1986 Volume I Fetal 352 pages approx 0 407 00450 5 £50.00 approx

Volume II Neonatal 488 pages approx 0 407 00451 3 £60.00 approx

Set 0 407 00378 9 £95.00 approx

## PEDIATRIC NUTRITION: Theory and Practice

**Richard J Grand, MD, James L Sutphen, MD, and William H Dietz Jr, MD**

There is an emergent understanding of the impact that acute and chronic disease has on nutritional status, accompanied by concepts of nutritional rehabilitation. Nutritional care of pediatric patients with devastating illness or injury has been improved in recent years by the use of parenteral and enteral nutrition. This volume provides both theoretical and practical guidelines by which appropriate nutritional care can be set by making practitioners familiar with the principles and practice of nutrition.

January 1987 1024 pages Illustrated 0 409 95111 0 £103.00 approx

## GENETIC AND METABOLIC DISEASE IN PAEDIATRICS

**BIMR Pediatrics – Volume 5**

**June K Lloyd and C R Scriver**

1985 328 pages 234 × 165 mm Hardcover Illustrated 0 407 02312 7 £45.00

## NEONATAL AND PEDIATRIC RESPIRATORY MEDICINE

**BIMR Pediatrics – Volume 4**

**Professor A D Milner and Richard Martin**

1985 256 pages 234 × 165 mm Hardcover Illustrated 0 407 02311 9 £40.00

## PEDIATRIC NUTRITION • BIMR Pediatrics – Volume 3

Edited by **Gavin C Arneil** and **Jack Metcalf**




1985 296 pages 234 × 165 mm Hardcover Illustrated 0 407 02310 0 £40.00

Please order these titles from your usual bookseller – or in case of difficulty from Butterworths at the address below.



**Butterworths**  
*meeting professional needs*





# Pure innovation revealed

## The range of human insulins from Nordisk and Wellcome



Full prescribing information available on request from either:-

Nordisk-UK  
Highview House  
Tottenham Crescent  
Epsom (KT18 8Q)  
Tel. No: Burgh Heath (07373) 60621

The Wellcome Foundation Ltd.  
Crewe Hall  
Crewe  
Cheshire CW11 1UB  
Tel. No: Crewe (0270) 583151

Human  
● **INSULATARD**  
(Isophane Insulin  
Injection [NPH],  
highly purified  
human insulin [emp])

Human  
● **VELOSULIN**  
(Neutral Insulin  
Injection, highly  
purified human  
insulin [emp])

Human  
● **MIXTARD 30/70**  
(Neutral suspension  
comprising 30% Neutral  
Insulin Injection and 70%  
Isophane Insulin  
Injection [NPH] - human  
insulin [emp])

Human  
● **INITARD 50/50**  
(Neutral suspension  
comprising 50% Neutral  
Insulin Injection and 50%  
Isophane Insulin  
Injection [NPH] - human  
insulin [emp])

**HUMAN INITARD 50/50** (Neutral Suspension comprising 50% Neutral Insulin Injection and 50% Isophane Insulin Injection [NPH]). **HUMAN VELOSULIN**, **HUMAN INSULATARD**, **HUMAN MIXTARD 30/70** and **HUMAN INITARD 50/50** are manufactured from highly purified human insulin (emp). **PRESENTATION** HUMAN VELOSULIN, HUMAN INSULATARD, HUMAN MIXTARD 30/70 and HUMAN INITARD 50/50 are available in 10ml vials containing 100iu/ml. To provide sensory identification the metal sealing rings of the vial have tactile marks and the vials are also fitted with colour coded tamper-proof caps. **USES** Treatment of Insulin Dependent Diabetics. Human Velosulin is particularly suitable in the treatment of diabetic coma and precoma. **DOSAGE AND ADMINISTRATION** Dosage to be determined by the physician, according to the needs of the patient. Avoid accidental intra-vascular injection. **CONTRA-INDICATIONS AND WARNINGS** Insulin is contra-indicated in hypoglycaemia. In the event of overdosage, glucose should be given either orally or intravenously. Glucagon may also be administered. Human Insulatard, Human Mixtard 30/70, Human Initard 50/50, should not be given intravenously or intravascularly. Treatment with cortico-steroids, oral contraceptives or thyroid hormones may lead to an increase in dosage requirements. Beta-blockers may affect insulin requirements and mask hypoglycaemia. U100 insulin must only be used in U100 syringes. **PHARMACEUTICAL PRECAUTION** Store at 2 to 8 degrees C, protected from sunlight. Do not freeze. **LEGAL CATEGORY P** **BASIC NHS PRICE** HUMAN VELOSULIN, HUMAN INSULATARD, HUMAN MIXTARD 30/70 and HUMAN INITARD 50/50: 10 ml vial £6.95. **PRODUCT LICENCE NUMBERS** Human Velosulin 3132/0031 and 0003/0211. Human Insulatard 3132/0034 and 0003/0212. Human Mixtard 30/70 3132/0037 and 0003/0213. Human Initard 50/50 3132/0040 and 0003/0214.